Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT05885412

A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Led by Rocket Pharmaceuticals Inc. · Updated on 2026-04-16

9

Participants Needed

3

Research Sites

313 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.

CONDITIONS

Official Title

A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female 18 years or older at the time of signing informed consent
  • Able and willing to provide signed informed consent
  • Clinical diagnosis of Arrhythmogenic Cardiomyopathy by 2010 revised Task Force Criteria
  • Documented pathogenic or likely pathogenic truncating variant in PKP2
  • Implantable Cardioverter-Defibrillator (ICD) implanted at least 6 months before enrollment
  • Premature ventricular contraction (PVC) frequency of 500 or more per 24 hours by ambulatory rhythm monitoring
  • Left ventricular ejection fraction of 50% or higher by echocardiogram or cardiac MRI
Not Eligible

You will not qualify if you...

  • Neutralizing antibody titer against AAVrh.74 capsid greater than 1:40
  • Cardiomyopathy caused by genetic factors other than PKP2 truncating variant
  • Previous participation in gene transfer or gene editing studies
  • Severe dysfunction of the right ventricle
  • New York Heart Association Class IV heart failure

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

University of California, San Diego

La Jolla, California, United States, 92037

Actively Recruiting

2

Duke University

Durham, North Carolina, United States, 27710

Actively Recruiting

3

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

Withdrawn

Loading map...

Research Team

C

Clinical Information

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here